BlueCrest Capital Management Ltd bought a new position in PerkinElmer, Inc. (NYSE:PKI) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 6,453 shares of the medical research company’s stock, valued at approximately $440,000.

Other hedge funds also recently modified their holdings of the company. Envestnet Asset Management Inc. grew its stake in PerkinElmer by 28.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,979 shares of the medical research company’s stock worth $115,000 after acquiring an additional 434 shares in the last quarter. Acrospire Investment Management LLC grew its stake in PerkinElmer by 185.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the medical research company’s stock worth $136,000 after acquiring an additional 1,300 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in PerkinElmer in the 1st quarter worth about $152,000. LS Investment Advisors LLC grew its stake in PerkinElmer by 2.1% in the 2nd quarter. LS Investment Advisors LLC now owns 2,877 shares of the medical research company’s stock worth $196,000 after acquiring an additional 60 shares in the last quarter. Finally, Capital Asset Advisory Services LLC bought a new position in PerkinElmer in the 2nd quarter worth about $222,000. Institutional investors and hedge funds own 91.47% of the company’s stock.

WARNING: “BlueCrest Capital Management Ltd Buys Shares of 6,453 PerkinElmer, Inc. (PKI)” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://theolympiareport.com/2017/10/17/bluecrest-capital-management-ltd-buys-shares-of-6453-perkinelmer-inc-pki.html.

Several brokerages have recently weighed in on PKI. Cowen and Company reaffirmed a “market perform” rating and issued a $70.00 price target (up previously from $61.00) on shares of PerkinElmer in a research report on Tuesday, June 20th. Wells Fargo & Company began coverage on shares of PerkinElmer in a research report on Thursday, July 13th. They issued a “market perform” rating and a $72.00 price target for the company. Zacks Investment Research cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $67.00 price target on shares of PerkinElmer in a research report on Tuesday, September 26th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating on shares of PerkinElmer in a research report on Sunday, July 16th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $67.77.

PerkinElmer, Inc. (NYSE:PKI) opened at 71.25 on Tuesday. PerkinElmer, Inc. has a 12-month low of $45.35 and a 12-month high of $72.11. The firm has a 50 day moving average of $68.78 and a 200-day moving average of $64.95. The stock has a market cap of $7.85 billion, a PE ratio of 21.49 and a beta of 0.72.

PerkinElmer (NYSE:PKI) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The business had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. The company’s revenue was up 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 EPS. On average, analysts expect that PerkinElmer, Inc. will post $2.89 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 10th. Stockholders of record on Friday, October 20th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, October 19th. This represents a $0.28 annualized dividend and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio is presently 8.46%.

PerkinElmer Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.